Overview
GE Healthcare Q3 revenue grows 6% yr/yr, beating analyst expectations
Adjusted EPS for Q3 beats consensus, despite tariff impacts
Company raises lower end of full-year 2025 Adjusted EPS guidance
Outlook
GE HealthCare raises lower end of full-year 2025 Adjusted EPS guidance to $4.51-$4.63
Company expects 2025 organic revenue growth of approximately 3% year-over-year
GE HealthCare anticipates 2025 free cash flow of at least $1.4 bln
Result Drivers
REGIONAL PERFORMANCE - Revenue growth driven by strong demand in EMEA and US
SEGMENT CONTRIBUTION - Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics led revenue performance
TARIFF IMPACTS - Tariffs affected margins and EPS, partially offset by volume and price benefits
GE Healthcare shares gained 4.5% in premarket trading.
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $5.10 bln | $5.08 bln (13 Analysts) |
Q3 Adjusted EPS | Beat | $1.07 | $1.05 (13 Analysts) |
Q3 EPS | $0.98 | ||
Q3 Net Income | $446 mln | ||
Q3 Adjusted Free Cash Flow | $593 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for GE Healthcare Technologies Inc is $88.00, about 9.8% above its October 28 closing price of $79.40
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago
Press Release: ID:nBw29ckRna
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.